MX2018011293A - Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma. - Google Patents

Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.

Info

Publication number
MX2018011293A
MX2018011293A MX2018011293A MX2018011293A MX2018011293A MX 2018011293 A MX2018011293 A MX 2018011293A MX 2018011293 A MX2018011293 A MX 2018011293A MX 2018011293 A MX2018011293 A MX 2018011293A MX 2018011293 A MX2018011293 A MX 2018011293A
Authority
MX
Mexico
Prior art keywords
cysteamine
prolonged release
salt
pharmaceutical composition
release pharmaceutical
Prior art date
Application number
MX2018011293A
Other languages
English (en)
Inventor
Gazzaniga Andrea
Cerea Matteo
Maroni Alessandra
BARCHIELLI Marco
Original Assignee
Recordati Ind Chimica E Farmaceutica S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ind Chimica E Farmaceutica S P A filed Critical Recordati Ind Chimica E Farmaceutica S P A
Publication of MX2018011293A publication Critical patent/MX2018011293A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe una forma de dosificación de unidad múltiple de liberación prolongada, preferiblemente perlas, de cisteamina, cistamina o una sal farmacéuticamente aceptable de la misma, preferiblemente bitartrato de cisteamina, con un recubrimiento no gastro resistente. La forma de dosis está particularmente indicada para la administración a pacientes una o dos veces al día y puede ser utilizada también para administración pediátrica.
MX2018011293A 2016-03-18 2017-03-14 Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma. MX2018011293A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITUA2016A001799A ITUA20161799A1 (it) 2016-03-18 2016-03-18 Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
PCT/EP2017/055964 WO2017157922A1 (en) 2016-03-18 2017-03-14 Prolonged release pharmaceutical composition comprising cysteamine or salt thereof

Publications (1)

Publication Number Publication Date
MX2018011293A true MX2018011293A (es) 2019-02-13

Family

ID=56203798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011293A MX2018011293A (es) 2016-03-18 2017-03-14 Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.

Country Status (14)

Country Link
US (1) US11135173B2 (es)
EP (1) EP3429565B1 (es)
JP (1) JP2019508441A (es)
KR (1) KR102361246B1 (es)
AU (1) AU2017234169B2 (es)
CA (1) CA3013429A1 (es)
CO (1) CO2018009543A2 (es)
EA (1) EA201891860A1 (es)
ES (1) ES2879810T3 (es)
IL (1) IL261087B (es)
IT (1) ITUA20161799A1 (es)
MX (1) MX2018011293A (es)
UA (1) UA123782C2 (es)
WO (1) WO2017157922A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
IT201700064875A1 (it) * 2017-06-12 2018-12-12 Sicit 2000 Spa Sistemi multistrato idrorepellenti a rilascio controllato di principi attivi in acqua e nel terreno.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004075A1 (en) * 2000-12-13 2005-01-06 Walcom Animal Science (I.P.2) Limited Composition for regulating animal growth, method of manufacture and use thereof
CN100391448C (zh) * 2003-11-19 2008-06-04 奥加生物药业(I.P.1)有限公司 提高乙醇代谢和减轻宿醉效应的物质和方法
BRPI0707277B1 (pt) * 2006-01-27 2021-07-13 The Regents Of The University Of California Composição, uso da mesma,e , formulação famacêutica
ATE525065T1 (de) * 2006-07-10 2011-10-15 Pfleger R Chem Fab Pharmazeutische zubereitung für die orale verabreichung mit gesteuerter wirkstofffreisetzung im dünndarm und verfahren zu ihrer herstellung
JP5583022B2 (ja) * 2007-11-30 2014-09-03 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア システアミン生成物を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の治療方法
CN101653426A (zh) * 2009-09-16 2010-02-24 冯利萍 一种高稳型半胱胺盐酸盐的缓释小丸及制备方法
WO2011077451A2 (en) 2009-12-22 2011-06-30 Abbott Healthcare Private Limited Controlled release pharmaceutical composition
KR20140125644A (ko) * 2013-04-19 2014-10-29 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 레프리젠티드 바이 더 세크러터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비스즈 종양 전이의 저해에 있어서의 시스테아민 및 그의 유도체의 용도
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法

Also Published As

Publication number Publication date
CA3013429A1 (en) 2017-09-21
IL261087A (en) 2018-10-31
AU2017234169B2 (en) 2023-01-12
AU2017234169A1 (en) 2018-08-16
UA123782C2 (uk) 2021-06-02
WO2017157922A1 (en) 2017-09-21
EP3429565A1 (en) 2019-01-23
ES2879810T3 (es) 2021-11-23
CO2018009543A2 (es) 2018-10-10
EP3429565B1 (en) 2021-06-09
KR102361246B1 (ko) 2022-02-09
ITUA20161799A1 (it) 2017-09-18
US20190076368A1 (en) 2019-03-14
IL261087B (en) 2021-10-31
BR112018068155A2 (pt) 2019-02-12
KR20180120268A (ko) 2018-11-05
EA201891860A1 (ru) 2019-02-28
JP2019508441A (ja) 2019-03-28
US11135173B2 (en) 2021-10-05

Similar Documents

Publication Publication Date Title
JP2015057451A5 (es)
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington&#39;s disease
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
NZ714963A (en) Compositions and methods for treating anemia
MX2021016109A (es) Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion.
MX2021002321A (es) Nuevos metodos.
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018011293A (es) Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.
PH12018500817A1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
MY193963A (en) Composition for treating joint diseases and kit containing same
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
MX2017000384A (es) Forma de dosificacion en capsulas de succinato de metoprolol.
MX2018011685A (es) Proceso para formulaciones solidas de mesalazina.
MX2016006375A (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
PH12019501607A1 (en) Tapentadol nasal composition
PL414785A1 (pl) Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną
WO2016187595A3 (en) Oral pharmaceutical composition of methylergonovine
MD4458B1 (ro) Utilizarea preparatului Polibiolină în tratamentul bolnavilor cu ciroză hepatică
PL2852400T3 (pl) Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym, zastosowanie analogu insuliny, sposób dawkowania oraz sposób leczenia cukrzycy
UA101141U (uk) Спосіб корекції дисліпідемії у хворих на інфаркт міокарда у поєднанні з неалкогольним стеатогепатитом